<DOC>
	<DOCNO>NCT02827344</DOCNO>
	<brief_summary>Immunotherapy probably , since development therapy target EGFR mutation ALK rearrangement , attractive therapeutic perspective management metastatic lung cancer . Among compound test , inhibitor immune checkpoint PROGRAMME DEATH 1 / PROGRAMME DEATH LIGAND 1 ( PD-1/PD-L1 ) test numerous clinical trial recently publish positive result lead approval one drug USA expand access program two drug France . PROGRAMME DEATH LIGAND 1 ( PD-L1 ) expression tumor cell strongly associate response molecule participation various clinical trial currently reserve patient express biomarker therefore justifies new invasive biopsy ( bronchoscopic CT-guided ) represent considerable drag access treatment . Circulating tumor cell ( CTCs ) isolate Isolation Size Tumor Cells ( ISET ) offer direct non-invasive access tumor . It already demonstrate molecular characterization ( EGFR , ALK ) blood sample possible . We propose demonstrate feasibility analysis PDL-1 expression cell immunocytochemistry . Myeloid-Derived Suppressor Cells ( MDSCs ) immature myeloid cell inhibit T cell function thus promote tumor growth . These cell frequently express PD-L1 . We propose test whether MDSCs level evolution treatment PD1 inhibitor correlate response drug . The main objective study demonstrate feasibility analysis PD-L1 expression CTC</brief_summary>
	<brief_title>PDL-1 Expression Circulating Tumor Cells Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<criteria>Stage IV nonsmall cell lung cancer patient prior start immunotherapy treatment Patients World Health Organization ( WHO ) performance status 03 Patients informed non opposition form sign investigator Patients healthcare insurance system affiliation Prior malignancy within 5 year study entry Refusal participate Patient legal protection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>PD-1/PD-L1</keyword>
	<keyword>Immune checkpoint</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>lung cancer</keyword>
	<keyword>circulate tumor cell</keyword>
	<keyword>immunocytochemistry</keyword>
	<keyword>ISET</keyword>
	<keyword>MDSC</keyword>
	<keyword>Stage IV non-small cell lung cancer</keyword>
</DOC>